Evofem Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value and share data)
| As of | ||
|---|---|---|
| December 31, 2025 | December 31, 2024 | |
| Assets | ||
| Current assets: | ||
| Restricted cash and cash equivalents | $578 | $741 |
| Trade accounts receivable, net | 12,480 | 9,832 |
| Inventories | 1,129 | 1,577 |
| Prepaid and other current assets | 1,097 | 1,459 |
| Total current assets | 15,284 | 13,609 |
| Property and equipment, net | 418 | 458 |
| Operating lease right-of-use assets | 182 | 89 |
| Intangible asset, net (Note 7) | 4,348 | 9,597 |
| Other noncurrent assets | 42 | 36 |
| Total assets | $20,274 | $23,789 |
| Liabilities, convertible and redeemable preferred stock and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $13,153 | $16,172 |
| Notes - carried at fair value (Note 4) | 20,097 | 14,974 |
| Notes - carried at fair value - Related Party (Note 4) | 1,352 | - |
| Convertible notes, net - Adjuvant - Related Party (Note 4) | 32,770 | 30,769 |
| Short-term debt | 147 | 135 |
| Accrued expenses | 1,292 | 5,509 |
| Accrued compensation | 2,587 | 3,494 |
| Operating lease liabilities – current | 128 | 82 |
| Derivative liabilities | 1,006 | 1,359 |
| Contingent liabilities - current (Note 7) | 272 | 592 |
| Other current liabilities | 12,016 | 7,362 |
| Total current liabilities | 84,820 | 80,448 |
| Operating lease liabilities - noncurrent | 54 | 7 |
| Contingent liabilities - noncurrent (Note 7) | 4,837 | 9,809 |
| Total liabilities | 89,711 | 90,264 |
| Commitments and contingencies (Note 7) | - | |
| Convertible and redeemable preferred stock, $0.0001 par value, senior to Common Stock | ||
| Series E-1, F-1 and G-1 convertible and redeemable preferred stock, 10,000, 95,000 and 5,000 shares authorized; 2,412 and 2,068 shares of E-1 issued and outstanding as of December 31, 2025 and 2024, respectively; 26,280 shares of F-1 issued and outstanding at both December 31, 2025 and 2024, and 1,618 shares of G-1 issued and outstanding at December 31, 2025 and no such shares issued and outstanding at December 31, 2024 | 4,899 | 4,782 |
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | - | - |
| Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 126,685,925 and 113,356,354 shares issued and outstanding as of and December 31, 2025 and 2024, respectively | 13 | 11 |
| Additional paid-in capital | 831,859 | 829,026 |
| Accumulated other comprehensive loss | (8,818) | (2,630) |
| Accumulated deficit | (897,390) | (897,664) |
| Total stockholders’ deficit | (74,336) | (71,257) |
| Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit | $20,274 | $23,789 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.